Table 3.

Uni- and multivariable analysis of prognostic factors for TTF2.

	N (N of events)	mTTF2 (95% CI)	HR univariable analysis	HR multivariable analysis
			(95% CI)	(95% CI)
Total cohort	167 (165)	1.9 (1.5–2.2)
Gender
Female	77 (76)	1.9 (1.3–2.4)
Male	90 (89)	1.9 (1.5–2.3)	1.24 (0.91–1.70) p = 0.166
Age
0–67 years	82 (80)	1.6 (1.2–2.1)
>67 years	85 (85)	1.9 (1.4–2.3)	1.17 (0.86–1.60) p = 0.323
Tumor spread
Locally advanced	22 (22)	3.7 (0.6–6.8)
Metastatic	145 (143)	1.8 (1.6–2.1)	1.52 (0.97–2.39) p = 0.065
ECOG PS
0–1	95 (93)	2.0 (1.5–2.4)
>1	27 (27)	1.4 (1.3–1.5)	1.72 (1.11–2.65) p= 0.013	2.05 (1.06–3.97) p= 0.032
CA19-9 (kU/L)
0–1,550	52 (51)	3.3 (1.4–5.2)
>1,550	51 (51)	1.4 (1.3–1.6)	2.02 (1.33–3.05) p= 0.001	2.03 (1.18–3.49) p= 0.010
Albumin (g/L)
<35	64 (64)	1.3 (0.8–1.9)
35–47	77 (75)	2.6 (1.3–3.8)	0.50 (0.36–0.71) p< 0.001	0.22 (0.12–0.40) p< 0.001
Regimen 1st line
Monotherapy	79 (79)	3.0 (2.2–3.8)
Combination therapy	88 (86)	4.3 (3.0–5.5)	0.79 (0.58–1.07) p = 0.122
Regimen 1st line
Gemcitabine	70 (70)	2.7 (1.9–3.5)
Gem/NabP	46 (45)	4.5 (2.5–6.5)	0.73 (0.50–1.07) p = 0.103
Regimen 2nd line
Monotherapy	68 (67)	1.8 (1.4–2.3)
Combination therapy	99 (98)	1.9 (1.2–2.5)	0.85 (0.62–1.17) p = 0.316
Regimen 2nd line
Cap or 5-FU/FA	51 (50)	1.8 (1.4–2.3)
Cap/Ox or 5-FU/FA/Ox	66 (66)	1.8 (1.4–2.2)	0.97 (0.81–1.17) p = 0.778
TTF1 (months)
0–3.65	83 (82)	1.7 (1.4–2.0)
>3.65	83 (82)	2.3 (1.7–2.9)	0.90 (0.66–1.22) p = 0.481

TTF2, Time to treatment failure in months from start of second line treatment; HR, Hazard ratio; CI, Confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; Gem/NabP, gemcitabine plus nab-paclitaxel; Cap, capecitabine; 5-FU/FA, 5-flourouracil plus folinic acid; Cap/Ox, capecitabine plus oxaliplatin; 5-FU/FA/Ox, 5-flourouracil, folinic acid, and oxaliplatin; TTF1, Time to treatment failure under first line treatment. All p values < 0.05 are typed in bold.